MET fusions are targetable genomic variants in the treatment of advanced malignancies.

Abstract excerpt

Targeted therapy for malignancies has developed rapidly in recent years, benefiting patients harboring genetic mutations sensitive to relevant tyrosine kinase inhibitors (TKIs). With the development of targeted sequencing techniques, an increasing number of detectable genomic alterations in malignancies, including MET fusions, have been revealed. MET fusions, although rare among malignancies, might be functional...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Proliferation
• Share to ErbB Receptors
• Share to Genomics